Sprint Bioscience AB (SPRINT) — Cash Flow-to-Debt Ratio
Sprint Bioscience AB (SPRINT) has a Cash Flow-to-Debt Ratio of -1.52x as of March 2026, meaning its operating cash flow of Skr-19.29 Million could theoretically repay -2% of its total liabilities (Skr12.69 Million) in one year. See how financially flexible is Sprint Bioscience AB to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sprint Bioscience AB Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Sprint Bioscience AB across 14 annual periods. For the full cash flow conversion analysis, see Sprint Bioscience AB cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Sprint Bioscience AB (2012–2025)
Year-by-year debt coverage analysis for Sprint Bioscience AB. Check Sprint Bioscience AB cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 4.78x | Skr83.53 Million | Skr17.48 Million | ▲ +770.6% |
| 2024 | -0.71x | Skr-23.36 Million | Skr32.78 Million | ▼ -207.8% |
| 2023 | 0.66x | Skr22.87 Million | Skr34.60 Million | ▲ +110.3% |
| 2022 | -6.40x | Skr-59.05 Million | Skr9.23 Million | ▼ -38.4% |
| 2021 | -4.62x | Skr-40.12 Million | Skr8.68 Million | ▼ -247.8% |
| 2020 | -1.33x | Skr-32.22 Million | Skr24.25 Million | ▲ +61.0% |
| 2019 | -3.40x | Skr-28.00 Million | Skr8.23 Million | ▼ -293.2% |
| 2018 | -0.87x | Skr-19.08 Million | Skr22.05 Million | ▲ +72.2% |
| 2017 | -3.12x | Skr-23.05 Million | Skr7.40 Million | ▼ -925.9% |
| 2016 | 0.38x | Skr7.93 Million | Skr21.03 Million | ▲ +1068.6% |
| 2015 | 0.03x | Skr833.54K | Skr25.81 Million | ▲ +101.4% |
| 2014 | -2.23x | Skr-10.76 Million | Skr4.83 Million | ▼ -156.8% |
| 2013 | -0.87x | Skr-3.57 Million | Skr4.11 Million | ▼ -21.3% |
| 2012 | -0.72x | Skr-2.29 Million | Skr3.20 Million | — |